Although many cell and animal experiments have demonstrated that FOXA1/FOXA2 knockout can significantly inhibit cancer progression, FOXAs themselves are undruggable targets for clinical application because of their intricate transcriptional network as transcription factors. The gene discussed is FOXA1; the disease is cancer.